Glucagon-Like Peptide-1 Receptor Agonists in Neurodegenerative Disorders

Glucagon-like peptide-1 receptor (GLP-1R) agonists, originally developed for glycaemic control in type 2 diabetes, have emerged as promising agents for the treatment of neurodegenerative disorders. These peptides cross the blood–brain barrier and engage receptors widely expressed in central nervous system regions implicated in motor and cognitive function. Preclinical studies demonstrate that GLP-1R activation modulates neuroinflammation, enhances mitochondrial function and synaptic plasticity, and reduces accumulation of pathological proteins such as α-synuclein and amyloid-β. Parallel epidemiological work suggests that diabetic patients receiving GLP-1R agonists may exhibit lower incidence or slower progression of Parkinson’s and Alzheimer’s diseases. Current research is extending these findings into controlled clinical trials of long-acting GLP-1 analogues, with the aim of repurposing a well-tolerated drug class to slow or halt neurodegenerative processes. The global burden of neurodegeneration, ageing demographics and the urgent need for disease-modifying therapies underline the significance of this approach.

Research from Nature Portfolio

No recent Nature Portfolio content available.

Glucagon-Like Peptide-1 Receptor Agonists in Neurodegenerative Disorders publication trend

The graph below shows the total number of articles in glucagon-like peptide-1 receptor agonists in neurodegenerative disorders across all publications each year (not limited to Nature Index journals).

Technical terms

Glucagon-like peptide-1 receptor (GLP-1R) agonist: A compound that binds to and activates the GLP-1 receptor, mimicking the incretin hormone’s effects on insulin secretion and neuroprotective signalling.

Nigrostriatal pathway: The dopamine-transporting neural projection from the substantia nigra to the striatum, critical for regulation of movement and commonly degenerated in Parkinson’s disease.

Neuroinflammation: The activation of the brain’s innate immune response, involving microglia and astrocytes, which can contribute to neuronal injury when chronically sustained.

Cohort study: An observational epidemiological design in which a defined group of individuals is followed over time to assess the relationship between exposures (e.g. diabetes) and outcomes (e.g. neurodegenerative disease).

References

1. A nationwide cohort study on diabetes severity and risk of Parkinson disease. npj Parkinson's Disease (2023).
2. Glucagon-like peptide 1 receptor stimulation reverses key deficits in distinct rodent models of Parkinson's disease. Journal of Neuroinflammation (2008).